Having trouble viewing this email? View in a browser.

You are subscribed to as %%emailaddr%%. Unsubscribe.

Dermatology Times eNews

Dermatology Times eNews

March 14, 2012


Radiation may turbocharge Yervoy against metastases

New York — Researchers at Memorial Sloan-Kettering Cancer Center say that radiating one tumor can trigger the immune system to kill other tumors in patients being treated with the cancer drug Yervoy (ipilimumab, Bristol-Myers Squibb). » More

Study: Vitamin A reduces melanoma risk

Oakland, Calif. — A new study suggests that vitamin A supplements can reduce the risk of developing melanoma. » More


Resource Center: Eczema: Emollients, Counseling, and Care

Folic Acid Supplements Up Risk of Eczema.


While You Are at the AAD...

Meet Amy Stankiewicz, Editor In Chief of Dermatology Times

Saturday March 17th 12-2 PM

Sunday March 18th 12-2 PM

Stop by booth #3041


Will the reported results of Yervoy and radiation mark a turning point in cancer treatment?

Yes | No | It’s promising | Too early to tell

Respond here and see what your colleagues are saying, too.

Want to see the results of our last survey regarding the “airplane notes” cheating scheme?
Click Here.



Are You This Good? Our claims are processed and paid in less than 20 days. Exact copays, coinsurances and deductibles are presented to the patient at time of service by our computer software. Our writeoffs are less than 4% of allowable charges.
Our Support Includes: All Billing Services, Reporting Packages and All Computer Software & Hardware.

Contact David Morell for a customized review & proposal (407)-875-2080 ext 1244
or at [email protected]
(407) 875-2080


Lawmakers postpone vote on indoor-tanning ban

Boise, Idaho — The Idaho House of Representatives’ decision to postpone a vote on a bill to ban indoor tanning by minors has elicited strong responses from both the Idaho Dermatology Society and the American Academy of Dermatology Association. » More


FDA approves dispenser for topical acne drug

Washington — The Food and Drug Administration has approved a pump dispenser for Galderma’s Differin (adapalene) Gel 0.3 percent, a retinoid indicated for the topical treatment of acne vulgaris in patients age 12 and older. » More

New Job Opportunities

Center for Dermatology Care


Cynthia Dreyer MD

Dr. Ira Schlesinger


David A High MD

Dermatology Associates of Lancaster


Madison Skin & Laser

Manhattan Dermatology


Minden Dermatology

Ochsner Health System


Universal Dermatology



Information Technology

Meetings & Events

Practice Management

Resource Centers


Follow us on Twitter

Digital Edition

View current edition

Powered by Modern Medicine Advanstar Medical Communications Group

You are subscribed to as %%emailaddr%%. Click here to unsubscribe or edit your member profile.

To ensure delivery to your inbox, please add us to your address book. If you need help doing this, Click here.

Advanstar Communications provides certain customer contact data (such as customers' names, addresses, phone numbers and e-mail addresses) to third parties who wish to promote relevant products, services and other opportunities which may be of interest to you. If you do not want Advanstar Communications to make your contact information available to third parties for marketing purposes, simply call (toll free) 866-529-2922 at any time, or fax us at 218-740-6417. Outside the U.S., please phone 218-740-6395. Contact us by mail at Advanstar Communications Inc., 131 West First St., Duluth, MN 55802-2065, USA.